Northwell Health’s Feinstein Institutes for Medical Research received a $500,000 RADx Tech award to develop a non-invasive endometriosis biomarker test using menstrual samples. The project, part of the Research OutSmarts Endometriosis (ROSE) program, uses single-cell RNA sequencing of menstrual samples to build a biomarker panel intended for FDA approval. Feinstein said ROSE studies have enrolled more than 3,700 participants, and ROSE 2 clinical trial began in 2022 and is currently enrolling. The award follows prior funding including an $18.3 million ARPA-H grant for a related innovation effort and a top prize in the RADx Tech ACT ENDO Challenge last month tied to an RNA-based assay from Endometrics. For developers of diagnostics, the funding reinforces the trajectory of menstrual-sample biomarker platforms from discovery into prospective clinical validation—an area where regulatory endpoints and specimen standardization can make or break commercialization.